Highlights

  • TruScreen recorded product sales of NZD 860k in 1H FY2026 and maintains FY2026 revenue guidance of NZD 2.8m.
  • New distributor appointments in India and South Africa, along with DaltonBio partnership, expand product access.
  • Public screening programs in Vietnam, Zimbabwe, and Uzbekistan are expected to contribute to 2H FY2026 revenue.

TruScreen Group Limited (NZX:TRU) released its unaudited interim results for the six months ended 30 September 2025 (1H FY2026). The company reported product sales of NZD 860k, representing a 17% decrease compared with the same period last year, mainly due to the deferral of NZD 200k in revenue to 2H FY2026.

Operating loss for the half-year increased to NZD 1.36m (1H FY2025: NZD 1.13m), reflecting costs associated with a capital raise completed in June 2025. Net operating cash outflow rose to NZD 1.7m (1H FY2025: NZD 0.9m) due to lower receipts from customers, higher prepayments to the contract manufacturer, and timing of the Australian R&D tax offset refund of NZD 460k, expected in 2H FY2026. Cash and cash equivalents as of 30 September 2025 stood at NZD 2.2m.

Market Developments

China
Consumable sales of Single Use Sensors (SUS) in China totaled 80,000 units, an 11% decrease from FY2025, attributed to production delays. Distribution focuses on key provinces including Beijing, Jiangsu, Guangdong, Shanghai, and Zhejiang, with channels expanded to Traditional Chinese Medicine hospitals, private luxury hospitals, and health check clinics.

Vietnam
The Vietnamese public screening program, initially planned to screen 260,000 women over five years, faced administrative delays. Training of community health workers and pilot screenings have begun, with full program management by the Ho Chi Minh City CDC expected in 2H FY2026.

India
TruScreen re-entered India with the appointment of Renovate Biologicals Pvt Ltd (RBL) as distributor. RBL has begun registration of DaltonBio HPV DNA products, and first sales have been recorded. A public screening program in Leh Town, Ladakh, was initiated by a Singapore volunteer gynecological team.

Other Regions
TruScreen anticipates initial revenues in 2H FY2026 from pilot programs in Uzbekistan and Indonesia. Zimbabwe screening will resume in 2H FY2026 with 20,000 women expected to be screened. South Africa has a newly appointed distributor, AIR, with product registration expected shortly. Distribution activities are also progressing in Thailand, Malaysia, and Singapore.

Corporate Activity

In June-July 2025, TruScreen completed a capital raise of NZD 4m through a Share Purchase Plan and Share Placement. The Company issued 190,716,031 share options linked to new shares, with an exercise price of NZD 0.022 expiring on 17 July 2026. Christine Pears was appointed to the Board following the retirement of Juliet Hull.

Share Price Snapshot
TRU was trading at NZD 0.0180 per share as of 28 November 2025.